{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Alwaqfi NR"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through angiotensin converting enzyme 2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, and also causing acute cardiac injury and chronic damage to the cardiovascular system. The purpose of this review is primarily reviewing the COVID-19 disease, including pathogen, clinical features, diagnosis, and treatment with particular attention to cardiovascular involvement based on the current evidence. COVID-19 remains a threat to global public health. The associated extra-pulmonary manifestations and their prolonged consequences are frequently overlooked. Pre-existing cardiovascular disease or acute cardiac complications may contribute to adverse early clinical outcome. At the moment, there is no specific treatment for COVID-19, but multiple randomized controlled trials (RCT) are being conducted. New supportive therapies are being evaluated with promising results."],"journal":["Journal of cardiothoracic surgery"],"pagination":["239"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7480628"],"repository":["biostudies-literature"],"pubmed_title":["COVID-19: an update and cardiac involvement."],"pmcid":["PMC7480628"],"pubmed_authors":["Ibrahim KS","Alwaqfi NR"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19: an update and cardiac involvement.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through angiotensin converting enzyme 2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, and also causing acute cardiac injury and chronic damage to the cardiovascular system. The purpose of this review is primarily reviewing the COVID-19 disease, including pathogen, clinical features, diagnosis, and treatment with particular attention to cardiovascular involvement based on the current evidence. COVID-19 remains a threat to global public health. The associated extra-pulmonary manifestations and their prolonged consequences are frequently overlooked. Pre-existing cardiovascular disease or acute cardiac complications may contribute to adverse early clinical outcome. At the moment, there is no specific treatment for COVID-19, but multiple randomized controlled trials (RCT) are being conducted. New supportive therapies are being evaluated with promising results.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2020-10-09T07:06:36Z","creation":"2020-09-14T07:16:34Z"},"accession":"S-EPMC7480628","cross_references":{"pubmed":["32907637"],"doi":["10.1186/s13019-020-01299-5"]}}